BioMarin Pharmaceutical (BMRN) Stock Price Up 2.5%

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose 2.5% during mid-day trading on Thursday . The stock traded as high as $87.40 and last traded at $89.37. Approximately 73,979 shares changed hands during trading, a decline of 93% from the average daily volume of 1,052,553 shares. The stock had previously closed at $87.16.

Several brokerages have weighed in on BMRN. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, March 22nd. Wedbush reiterated an “outperform” rating and set a $127.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 7th. Cantor Fitzgerald lifted their price target on BioMarin Pharmaceutical to $131.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Oppenheimer lowered their price target on BioMarin Pharmaceutical from $92.00 to $81.00 in a report on Friday, February 22nd. Finally, Barclays reiterated a “hold” rating and set a $95.00 price target on shares of BioMarin Pharmaceutical in a report on Sunday, February 24th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. BioMarin Pharmaceutical has an average rating of “Buy” and an average price target of $116.00.

The company has a debt-to-equity ratio of 0.28, a current ratio of 3.83 and a quick ratio of 2.76. The company has a market cap of $14.73 billion, a P/E ratio of -271.41 and a beta of 1.46.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, April 25th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. BioMarin Pharmaceutical had a negative return on equity of 2.97% and a negative net margin of 5.90%. The firm had revenue of $400.70 million for the quarter, compared to the consensus estimate of $389.95 million. During the same quarter in the previous year, the company posted $0.12 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post -0.06 earnings per share for the current fiscal year.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 2,196 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $95.00, for a total value of $208,620.00. Following the transaction, the insider now owns 142,504 shares in the company, valued at $13,537,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $82.16, for a total value of $328,640.00. Following the completion of the transaction, the chief executive officer now owns 326,520 shares in the company, valued at approximately $26,826,883.20. The disclosure for this sale can be found here. Insiders sold 103,011 shares of company stock worth $9,215,368 in the last 90 days. Corporate insiders own 1.90% of the company’s stock.

Several large investors have recently made changes to their positions in BMRN. Doyle Wealth Management acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth about $26,000. Rational Advisors LLC raised its holdings in BioMarin Pharmaceutical by 3,211.1% in the 1st quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 289 shares in the last quarter. Commonwealth Bank of Australia raised its holdings in BioMarin Pharmaceutical by 49.6% in the 4th quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Lindbrook Capital LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at approximately $30,000. Finally, PRW Wealth Management LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at approximately $30,000. 99.55% of the stock is owned by institutional investors.

WARNING: “BioMarin Pharmaceutical (BMRN) Stock Price Up 2.5%” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.themarketsdaily.com/2019/05/16/biomarin-pharmaceutical-bmrn-stock-price-up-2-5.html.

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also: What is Liquidity?

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.